Objective:
To evaluate the investigational oral gildeuretinol for Stargardt disease in a global phase 3 trial.
Approach:
- Trial Design: The NORTHSTAR trial will enroll approximately 230 patients, randomized 1:1 to receive either placebo or gildeuretinol, taken orally once daily for 2 years.
- Endpoints: The primary endpoint is the change in the rate of growth of retinal atrophic lesions from month 6 to month 24. A key secondary endpoint is the change in low-luminance visual acuity from baseline.
Key Findings:
- Gildeuretinol has entered late-stage clinical development.
Interpretation:
Conclusion:
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.